Long-term survival and predictors of mortality in Coronat)' Heart Disease

Coronruy heart disease (CHD) is by far the most important cause of death, and a main cause of disability in the Netherlands. Accordingly, coronruy heart disease has a great impact on society. In 1995 cardiac death occurred in about 40,000 persons (28% of all monality) and ischemic heart disease was the reason for 170,000 hospital admissions. I Since the 1980s an inunediate benefit is achieved in patients with acute manifestations of CHD, with pharmacologic therapy such as thrombolytic therapy in patients with evolving myocru·dial infarction and coronary interventions such as coronary aorto bypass graft surgery (CABG) and percutaneous transluminal coronary angioplasty procedure (PTCA). Together with improved secondalY prevention through diet, reduced smoking and medical regimens such as antiplatelets, beta-blockers, ace-inhibitors and statins the life expectancy has been improved. This resulted in an increase of patients with chronic manifestations of CHD including heart failure and a population of survivors with a

Long-term (>10 years) prognostic value of dobutamine stress echocardiography in a high-risk cohort

The prognostic value of dobutamine stress echocardiography (DSE) at >10-year follow-up is unknown. The aim of this study was to assess the very long-term prognostic value of DSE in a high-risk cohort of patients with known or suspected coronary artery disease. This prospective, single-center study included 3,381 patients who underwent DSE from January 1990 to January 2003. Two-dimensional echocardiographic images were acquired at rest, during dobutamine stress, and during recovery. Follow-up events were collected and included overall mortality, cardiac death, nonfatal myocardial infarction, and revascularization. The incremental value of DSE in the prediction of selected end points was evaluated using multivariate Cox proportional hazard analysis. During a mean follow-up of 13 ± 3.2 years (range 7.3 to 20.5 years), there were 1,725 deaths (51%), of which 1,128 (33%) were attributed to cardiac causes. Patients with an abnormal DSE had a higher mortality rate (44% vs 35% at 15-year follow-up, p <0.001) than those with a normal DSE. When comparing echocardiographic variables at rest to variables at maximum dose dobutamine, the chi-square of the test improved from 842 to 870 (p <0.0001) and from 684 to 740 (p <0.0001) for all-cause mortality and cardiac death, respectively. DSE provided incremental value in predicting all-cause mortality, cardiac death, and hard cardiac events. There seems, however, to be a "warranty period" of approximately 7 years, when the survival curves of a normal and abnormal DSE no longer diverge